Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (NCT07085767)
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
🩺 Plain-English Summary (8th-Grade Level)
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Hot Springs, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (181 Sites)
Showing the first 25 of 181 sites.
- Clinical Trial Site — Hot Springs, Arkansas
- Clinical Trial Site — Beverly Hills, California
- Clinical Trial Site — La Jolla, California
- Clinical Trial Site — Los Alamitos, California
- Clinical Trial Site — San Francisco, California
- Clinical Trial Site — Santa Barbara, California
- Clinical Trial Site — Vallejo, California
- Clinical Trial Site — Aurora, Colorado
- Clinical Trial Site — Denver, Colorado
- Clinical Trial Site — New Haven, Connecticut
- Clinical Trial Site — Tampa, Florida
- Clinical Trial Site — Marietta, Georgia
- Clinical Trial Site — Honolulu, Hawaii
- Clinical Trial Site — Peoria, Illinois
- Clinical Trial Site — Urbana, Illinois
- Clinical Trial Site — Ames, Iowa
- Clinical Trial Site — Scarborough, Maine
- Clinical Trial Site — Annapolis, Maryland
- Clinical Trial Site — Catonsville, Maryland
- Clinical Trial Site — Burlington, Massachusetts
- Clinical Trial Site — Minneapolis, Minnesota
- Clinical Trial Site — Jackson, Mississippi
- Clinical Trial Site — Kansas City, Missouri
- Clinical Trial Site — Santa Fe, New Mexico
- Clinical Trial Site — New York, New York
📞 Contact the Study Coordinator
Phone: (415) 651-7206
Email: OPERA-02@olema.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.